224 related articles for article (PubMed ID: 28025727)
1. Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events.
Wakabayashi H; Inada H; Nishioka Y; Hasegawa M; Nishioka K; Sudo A
Drugs R D; 2017 Mar; 17(1):233-239. PubMed ID: 28025727
[TBL] [Abstract][Full Text] [Related]
2. Maintenance of efficacy and safety with subcutaneous golimumab in rheumatoid arthritis patients with low disease activity who previously received TNF inhibitors.
Wakabayashi H; Inada H; Nishioka Y; Hasegawa M; Sudo A; Nishioka K
Clin Rheumatol; 2017 Apr; 36(4):941-946. PubMed ID: 27942977
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Maintenance of Golimumab Effectiveness for Injection Spacing in Rheumatoid Arthritis Patients with Low Disease Activity Who Previously Received Other TNF Inhibitors: Minimum 2-year Data From an Observational Study.
Wakabayashi H; Nagao N; Inada H; Nishioka Y; Hasegawa M; Nishioka K; Sudo A
Drugs R D; 2021 Sep; 21(3):351-357. PubMed ID: 34173221
[TBL] [Abstract][Full Text] [Related]
4. A real-world, multi-site, observational study of infusion time and treatment satisfaction with rheumatoid arthritis patients treated with intravenous golimumab or infliximab.
Daniel SR; McDermott JD; Le C; Pierce CA; Ziskind MA; Ellis LA
J Med Econ; 2018 Jul; 21(7):724-731. PubMed ID: 29718743
[TBL] [Abstract][Full Text] [Related]
5. Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54.
Alten R; Batko B; Hala T; Kameda H; Radominski SC; Tseluyko V; Babic G; Cronenberger C; Hackley S; Rehman M; von Richter O; Zhang M; Cohen S
RMD Open; 2019; 5(1):e000876. PubMed ID: 30997153
[TBL] [Abstract][Full Text] [Related]
6. Prediction of clinical response after 1 year of infliximab therapy in rheumatoid arthritis based on disease activity at 3 months: posthoc analysis of the RISING study.
Takeuchi T; Miyasaka N; Inui T; Yano T; Yoshinari T; Abe T; Koike T
J Rheumatol; 2015 Apr; 42(4):599-607. PubMed ID: 25684765
[TBL] [Abstract][Full Text] [Related]
7. Comparison of golimumab 100-mg monotherapy to golimumab 50 mg plus methotrexate in patients with rheumatoid arthritis: Results from a multicenter, cohort study.
Yonemoto Y; Okamura K; Takeuchi K; Ayabe K; Kaneko T; Matsushita M; Tamura Y; Iso T; Okura C; Otsuka K; Inoue H; Takagishi K
Mod Rheumatol; 2016; 26(1):24-8. PubMed ID: 26140464
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis.
Takeuchi T; Yamanaka H; Tanaka Y; Sakurai T; Saito K; Ohtsubo H; Lee SJ; Nambu Y
Mod Rheumatol; 2015; 25(6):817-24. PubMed ID: 25736355
[TBL] [Abstract][Full Text] [Related]
9. Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab.
Taylor PC; Ritchlin C; Mendelsohn A; Baker D; Kim L; Xu Z; Mack M; Kremer J
J Rheumatol; 2011 Dec; 38(12):2572-80. PubMed ID: 22089463
[TBL] [Abstract][Full Text] [Related]
10. A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis.
Westhovens R; Houssiau F; Joly J; Everitt DE; Zhu Y; Sisco D; Van Hartingsveldt B; Mascelli MA; Graham MA; Durez P; Bouman-Thio E
J Rheumatol; 2006 May; 33(5):847-53. PubMed ID: 16583466
[TBL] [Abstract][Full Text] [Related]
11. Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial.
Cohen SB; Radominski SC; Kameda H; Kivitz AJ; Tee M; Cronenberger C; Zhang M; Hackley S; Rehman MI; von Richter O; Alten R
BioDrugs; 2020 Apr; 34(2):197-207. PubMed ID: 31939063
[TBL] [Abstract][Full Text] [Related]
12. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
13. Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK).
Mueller RB; Gengenbacher M; Richter S; Dudler J; Möller B; von Kempis J
Arthritis Res Ther; 2016 Apr; 18():88. PubMed ID: 27074795
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of infliximab: A comparison with other biological disease-modifying anti-rheumatic drugs.
Kobayashi D; Ito S; Takai C; Hasegawa E; Nomura Y; Otani H; Abe A; Ishikawa H; Murasawa A; Narita I; Nakazono K
Mod Rheumatol; 2018 Jul; 28(4):599-605. PubMed ID: 28972441
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab.
Tanaka Y; Yamanaka H; Takeuchi T; Inoue M; Saito K; Saeki Y; Lee SJ; Nambu Y
Mod Rheumatol; 2017 Mar; 27(2):237-245. PubMed ID: 27586879
[TBL] [Abstract][Full Text] [Related]
16. Two-year Outcomes of Infliximab Discontinuation in Patients with Rheumatoid Arthritis: A Retrospective Analysis from a Single Center.
Takai C; Ito S; Kobayashi D; Nemoto T; Lee H; Abe A; Otani H; Nakazono K; Murasawa A; Ishikawa H
Intern Med; 2020; 59(16):1963-1970. PubMed ID: 32801270
[TBL] [Abstract][Full Text] [Related]
17. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
Moots RJ; Xavier RM; Mok CC; Rahman MU; Tsai WC; Al-Maini MH; Pavelka K; Mahgoub E; Kotak S; Korth-Bradley J; Pedersen R; Mele L; Shen Q; Vlahos B
PLoS One; 2017; 12(4):e0175207. PubMed ID: 28448562
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
19. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study).
Nam JL; Villeneuve E; Hensor EM; Conaghan PG; Keen HI; Buch MH; Gough AK; Green MJ; Helliwell PS; Keenan AM; Morgan AW; Quinn M; Reece R; van der Heijde DM; Wakefield RJ; Emery P
Ann Rheum Dis; 2014 Jan; 73(1):75-85. PubMed ID: 23912798
[TBL] [Abstract][Full Text] [Related]
20. The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients.
Bray VJ; Broadwell A; Baraf HSB; Black S; Brady BL; Tkacz J; Yarngo L; DeHoratius RJ
Drugs R D; 2018 Sep; 18(3):211-219. PubMed ID: 30054896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
